Background Direct oral anticoagulants (DOACs) are the treatment of choice for most patients
with atrial fibrillation and/or noncancer-associated venous thromboembolic disease …

Background: Non–vitamin K oral anticoagulants (NOACs) do not require routine laboratory
monitoring. However, laboratory measurement may be desirable in special situations and …

This guidance document was prepared on behalf of the International Council for
Standardization in Haematology (ICSH) for providing haemostasis-related guidance …

In 2018, the International Council for Standardization in Haematology (ICSH) published a
consensus document providing guidance for laboratories on measuring direct oral …

Direct oral anticoagulants (DOACs) offer noninferior efficacy and improved safety compared
to vitamin K antagonists (VKAs) for the prevention and treatment of venous …

Background Use of vitamin K antagonists for the prevention of stroke and systemic embolism
in dialysis patients with nonvalvular atrial fibrillation is controversial. However, no good …

The direct oral anticoagulants (DOACs), now including dabigatran, apixaban and
rivaroxaban, have given clinicians alternative options to low molecular weight heparins …

A new generation of antithrombotic agents has recently emerged. These provide direct
inhibition of either thrombin (factor IIa [FIIa]) or FXa, and are increasingly replacing the …

Direct oral anticoagulants (DOAC s), including the direct thrombin inhibitor, dabigatran, and
the direct factor Xa (FX a) inhibitors, rivaroxaban, apixaban and edoxaban, are approved for …

Oral vitamin K anticoagulation (warfarin, Coumadin, coumarin) has long been used for long-
term treatment and prophylaxis in a variety of clinical settings. Given the unpredictable …